Tuberculosis subunit vaccine design : the conflict of antigenicity and immunogenicity
The attempts to find an effective antituberculous subunit vaccine are based on the assumption that it must drive a Th1 response. In the absence of effective correlates of protection, a vast array of mycobacterial components are being evaluated worldwide either on the basis of their ability to be rec...
Veröffentlicht in: | Clinical immunology (Orlando, Fla.). - 1999. - 122(2007), 3 vom: 01. März, Seite 239-51 |
---|---|
1. Verfasser: | |
Weitere Verfasser: | , , |
Format: | Aufsatz |
Sprache: | English |
Veröffentlicht: |
2007
|
Zugriff auf das übergeordnete Werk: | Clinical immunology (Orlando, Fla.) |
Schlagworte: | Journal Article Research Support, Non-U.S. Gov't Review Antigens, Bacterial Tuberculosis Vaccines Vaccines, Subunit |
Zusammenfassung: | The attempts to find an effective antituberculous subunit vaccine are based on the assumption that it must drive a Th1 response. In the absence of effective correlates of protection, a vast array of mycobacterial components are being evaluated worldwide either on the basis of their ability to be recognized by T lymphocytes in in vitro assays during early stage of animal or human infection (antigenicity) or their capacity to induce T cell response following immunization in animal models (immunogenicity). The putative vaccine candidates selected using either of these strategies are then subjected to challenge studies in different animal models to evaluate the protective efficacy. Here we review the outcome of this current scheme of selection of vaccine candidates using an 'antigenicity' or 'immunogenicity' criterion on the actual protective efficacy observed in experimental animal models. The possible implications for the success of some of the leading vaccine candidates in clinical trials will also be discussed |
---|---|
Beschreibung: | Date Completed 11.04.2007 Date Revised 13.02.2007 published: Print-Electronic Citation Status MEDLINE |
ISSN: | 1521-7035 |